nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—AGTR2—cardiovascular system—attention deficit hyperactivity disorder	0.0509	0.504	CbGeAlD
Tasosartan—AGTR2—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.0373	0.0415	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.025	0.0278	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0232	0.0258	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0227	0.0253	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0226	0.0251	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0199	0.0221	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0195	0.0217	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.017	0.0189	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0158	0.0175	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.0151	0.0168	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.0148	0.0165	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0148	0.0165	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0138	0.0153	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0135	0.015	CbGpPWpGaD
Tasosartan—AGTR1—forebrain—attention deficit hyperactivity disorder	0.0135	0.133	CbGeAlD
Tasosartan—AGTR2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.0134	0.0149	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.0131	0.0146	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.013	0.0144	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.0128	0.0142	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0128	0.0142	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.0124	0.0138	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.0122	0.0136	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.0121	0.0134	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.012	0.0134	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0118	0.0131	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0116	0.0129	CbGpPWpGaD
Tasosartan—AGTR1—cardiovascular system—attention deficit hyperactivity disorder	0.0114	0.113	CbGeAlD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0112	0.0125	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.011	0.0122	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.0106	0.0118	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.0104	0.0116	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.0103	0.0115	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0103	0.0114	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00961	0.0107	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00899	0.01	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00856	0.00952	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00838	0.00933	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00836	0.00929	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00809	0.009	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00796	0.00885	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00786	0.00874	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00786	0.00874	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00777	0.00864	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00761	0.00847	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00756	0.00841	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00741	0.00824	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00736	0.00818	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00732	0.00814	CbGpPWpGaD
Tasosartan—AGTR1—nervous system—attention deficit hyperactivity disorder	0.00731	0.0725	CbGeAlD
Tasosartan—AGTR1—central nervous system—attention deficit hyperactivity disorder	0.00704	0.0698	CbGeAlD
Tasosartan—AGTR2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00685	0.00761	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00673	0.00749	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00648	0.00721	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00635	0.00706	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00581	0.00646	CbGpPWpGaD
Tasosartan—AGTR1—brain—attention deficit hyperactivity disorder	0.00559	0.0554	CbGeAlD
Tasosartan—AGTR2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00534	0.00594	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00528	0.00587	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00514	0.00571	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00513	0.0057	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00508	0.00565	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00493	0.00549	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00483	0.00538	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00481	0.00535	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00472	0.00525	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00461	0.00513	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00459	0.00511	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00457	0.00509	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0045	0.005	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.0045	0.005	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00449	0.00499	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00444	0.00494	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00441	0.00491	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0044	0.00489	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00429	0.00477	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00417	0.00464	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00416	0.00462	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00415	0.00462	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00414	0.0046	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00408	0.00454	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00404	0.0045	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00403	0.00448	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00397	0.00442	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00392	0.00436	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00385	0.00428	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00378	0.0042	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00376	0.00418	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00366	0.00407	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00358	0.00398	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00346	0.00385	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.0034	0.00379	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00336	0.00374	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00335	0.00373	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00331	0.00368	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00313	0.00348	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00312	0.00347	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00296	0.00329	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00293	0.00326	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.0029	0.00322	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00279	0.0031	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00273	0.00304	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00273	0.00303	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00272	0.00303	CbGpPWpGaD
Tasosartan—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00268	0.0266	CbGeAlD
Tasosartan—AGTR1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00264	0.00293	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00263	0.00293	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00259	0.00288	CbGpPWpGaD
Tasosartan—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00258	0.0256	CbGeAlD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00256	0.00285	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00256	0.00285	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00253	0.00282	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00253	0.00282	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00248	0.00276	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00245	0.00273	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00241	0.00268	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00239	0.00265	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00238	0.00265	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00223	0.00248	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00222	0.00247	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00219	0.00244	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00189	0.00211	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00174	0.00194	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00172	0.00191	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00167	0.00186	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00166	0.00184	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00155	0.00173	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00154	0.00171	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.0015	0.00167	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.0015	0.00166	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00149	0.00166	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00148	0.00164	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00147	0.00163	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00146	0.00163	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00145	0.00161	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00144	0.0016	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.0014	0.00155	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00135	0.00151	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00135	0.0015	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00133	0.00148	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00131	0.00146	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00122	0.00136	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00102	0.00113	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000944	0.00105	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000888	0.000988	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000857	0.000953	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000826	0.000918	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000823	0.000916	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.0008	0.000889	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000791	0.00088	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000786	0.000874	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000786	0.000874	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00078	0.000868	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000776	0.000863	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000723	0.000804	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000506	0.000563	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000324	0.00036	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000268	0.000298	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000223	0.000248	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000223	0.000248	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00022	0.000244	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000204	0.000227	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000179	0.000199	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00017	0.000189	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000135	0.00015	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000134	0.000149	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	5.8e-05	6.45e-05	CbGpPWpGaD
